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eTable 1. Microbiologic isolates from blood 
 
 All Lived (n) Died (n, %) 
Gram positive 418 388 30 (7.2) 
Coagulase-negative Staphylococcus 258 235 23 (8.9) 
Staphylococcus aureus, methicillin sensitive 87 84 3 (3.4) 
Streptococcus agalactiae 28 26 2 (7.1) 
Staphylococcus aureus, methicillin resistant 19 19 0 
Enterococcus faecalis 16 15 1 (6.3) 
Streptococcus spp 7 7 0 
Clostridium perfringens 2 1 1 (50) 
Propionibacterium acnes  1 1 0 
Gram negative 149 104 45 (30.2) 
Escherichia coli 57 41 16 (28.1) 
Klebsiella pneumoniae 39 29 10 (25.6) 
Pseudomonas aeruginosa 15 4 11 (73.3) 
Serratia marcescens 15 12 3 (20) 
Enterobacter cloacae 10 10 0 
Enterobacter aerogenes 4 2 2 (50) 
Citrobacter spp 3 1 2 (66.7) 
Klebsiella oxytoca 3 2 1 (33.3) 
Rauoltella spp 2 2 0 
Prevotella bivia 1 1 0 
Fungus 15 13 2 (13.3) 
Candida albicans 10 9 1 (10) 
Candida spp 5 4 1 (20) 
Three patients had both Gram positive and Gram negative organisms isolated from blood (not listed in this table); all survived. 
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eFigure 2. nSOFA component profiles for survivors and nonsurvivors. All patient values (survivors 
and non-survivors) are shown. Violin plots represent group medians at each time point. Error bars represent interquartile 
ranges (IQR). A. Respiratory component. B. Cardiovascular component. C. Hematologic component. Comparisons by 
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eTable 2. nSOFA prognostic utility for mortality at single centers. 
Center AUROC 95% CI p value 
University of Florida, 2016-2018  
(31 survivors; 7 non-survivors) 
   
T0 0.9516 0.8868 to 1.000 <0.001 
T6 0.9562 0.8842 to 1.000 <0.001 
T12 0.9562 0.8746 to 1.000 <0.001 
Columbia University (Irving), 2013-2018 
(53 survivors; 6 non-survivors) 
   
T0 0.9403 0.8599 to 1.000 <0.001 
T6 0.9560 0.8774 to 1.000 <0.001 
T12 0.9088 0.7524 to 1.000 0.02 
Amsterdam University, 2017-2018 
(67 survivors; 17 non-survivors) 
   
T0 0.7103 0.5499 to 0.8707 0.008 
T6 0.8705 0.7672 to 0.9738 <0.001 
T12 0.7904 0.6143 to 0.9664 0.002 
Beth Israel Deaconess, Harvard University, 
2010-2019 
(102 survivors; 9 non-survivors) 
   
T0 0.8170 0.6435 to 0.9905 0.002 
T6 0.8897 0.7342 to 1.000 <0.001 
T12 0.8235 0.5935 to 1.000 0.01 
Washington University, 2015-2019 
(114 survivors; 32 non-survivors) 
   
T0 0.7133 0.6088 to 0.8177 <0.001 
T6 0.7691 0.6791 to 0.8591 <0.001 
T12 0.7772 0.6835 to 0.8708 <0.001 
University of Virginia, 2011-2019  
(162 survivors; 13 non-survivors) 
   
T0 0.8872 0.8145 to 0.9600 <0.001 
T6 0.9318 0.8827 to 0.9810 <0.001 
T12 0.9405 0.8789 to 1.000 <0.001 
Vanderbilt University, 2017-2019  
(27 survivors; 13 non-survivors) 
   
T0 0.7293 0.5694 to 0.8893 0.02 
T6 0.7660 0.6121 to 0.9199 0.01 
T12 0.8316 0.7051 to 0.9582 0.002 
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eFigure 3. Utility of the maximum nSOFA score at either T0 or T6 (nSOFAmax T0, T6). A. Violin plot 
of the nSOFAmax T0, T6 for survivors and non-survivors. Black bars represent the median and interquartile range. 
Comparison by Mann-Whitney. B. Area under receiver operating characteristics curve (AUROC) for death, p<0.001. C. 
Predicted (red band with 95% confidence intervals) versus observed (solid line) mortality using the nSOFAmax T0, T6. * 
designates p-value <0.001. 
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eTable 3. nSOFA scores by timepoint among survivors and non-survivors by scoring group. 
 nSOFA score    
 0-3 4-7 8-11 ≥12 Deaths  (during interval) 
 Deaths 
(cumulative)  
T0 lived (n) 428 79 46 3 NA  NA 
T0 died (n) 31 21 38 7 NA  NA 
T6 lived (n) 420 87 46 3 NA  NA 
T6 died (n) 15 27 28 20 7  7 
T12 lived (n) 421 87 43 5 NA  NA 
T12 died (n) 14 19 22 19 16  23 
T24 lived (n) 421 97 29 9 NA  NA 
T24 died (n) 10 16 12 16 20  43 
T48 lived (n) 420 100 28 8 NA  NA 
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eFigure 4. Likelihood ratios for mortality by nSOFA score cutoff at T0, T6, T12 and for the 
nSOFAmax T0, T6. The mortality rate among patients with an nSOFAmax at T0 or T6 of <4 was 2.4%, whereas mortality 
occurred in 81% with nSOFAmax at T0 or T6 of >10. The likelihood ratio for mortality progressively increased as the 




© 2021 Fleiss N et al. JAMA Network Open. 
eFigure 5. Performance of nSOFA among infants <25 weeks.  
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eFigure 5 continued. All patient values (survivors and non-survivors) are shown. Violin plots represent group 
medians at each time point. Error bars represent interquartile ranges (IQR). A. Comparison of nSOFA scores among 
survivors <25 weeks and >25 weeks. B. Comparison of nSOFA scores among non-survivors <25 weeks and >25 weeks. 
C. nSOFA scores among <25 weeks GA survivors and non-survivors with late-onset infection. D. Area under receiver 
operating characteristics curves for the nSOFA to predict mortality in <25 week infants at T0, T6, and T12 time points (all 
p<0.001). Comparisons by Mann-Whitney. * designates p-value <0.001. ** designates p-value <0.05. 
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eFigure 6. Temporal progression of nSOFA scores among survivors and non-survivors. All 
patient values (survivors and non-survivors) are shown. Each row in the heat map represents a single patient. Each 
column represents a single time point. Patients in each group (survivors and non-survivors) are sorted by descending T0 
nSOFA scores. The cell color and intensity reflects the nSOFA score (legend). Black cells indicate mortality prior to the 
column time point. 
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eFigure 7. Temporal progression of individual patient nSOFA∆ dynamics among survivors and 
non-survivors. All patient values (survivors and non-survivors) are shown. Each row in the heat map represents a 
single patient. Each column represents a single time interval. The cell color and intensity reflects the nSOFA∆ over the 
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eFigure 8. Individual patient-level organ dysfunction dynamics among <25 weeks GA 
survivors and non-survivors. All patient values (survivors and non-survivors) are shown. Violin plots represent 
group medians at each time point. Error bars represent interquartile ranges (IQR). A. Pre-evaluation nSOFA∆ was most 
pronounced among non-survivors between T-48 and T0 [median 3 (IQR: 0, 6), T-24 and T0 (3 (0, 5)), and T-6 and T0 (2 
(0, 4); all p<0.001 by Mann-Whitney test]. B. nSOFA∆ at post-evaluation time points. C. Peri-evaluation nSOFA∆ 
differences increased proportionally to the length of time interval measured (T-6 to T6: median 3 (IQR: 1, 7); T-12 to T12: 
4 (1, 7) ; T-24 to T24: 5 (2, 8); and T-48 to T48: 7 (3, 10). For patients that died prior to a time point, the most recent 
nSOFA score was used for calculations. * designates p-value <0.001. ** designates p-value <0.05. 
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eFigure 9. Prevalence and temporal progression of organ dysfunction between survivors and 
non-survivors. Chord diagrams show each time point (A. T-48, B. T-24, C. T-12, D. T-6, E. T0, F. 
T6, G. T12, H. T24, I. T48). Ribbons connect patient groups (survivors, non-survivors) to organ 
systems [respiratory (RESP), cardiovascular (CV), hematologic (HEME)]. Ribbon thickness 
represents the percentage of patients in each category. Colored ribbons represent the presence of 
organ dysfunction (“+”; nSOFA > 0); grey ribbons within each component represent the absence of 
organ dysfunction (“-“; nSOFA = 0). The size of the outer band (yellow = survivors, black = non-
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eFigure 10. nSOFA scores for females and males. Violin plots represent group medians at each time point. 
Error bars represent interquartile ranges (IQR). A. Comparison of nSOFA scores among females. B. Comparison of 
nSOFA scores among males. C. Area under receiver operating characteristics curves for the nSOFA to predict mortality in 
female infants at T0, T6, and T12 time points (all p<0.001). D. Area under receiver operating characteristics curves for the 
nSOFA to predict mortality in male infants at T0, T6, and T12 time points (all p<0.001). E. Comparison of nSOFA scores 
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eFigure 11. nSOFA scores by pathogen classification. Violin plots represent group medians at each time 
point. Error bars represent interquartile ranges (IQR). A. Comparison of nSOFA scores among PATIENTS with gram-
positive bacteremia. B. Comparison of nSOFA scores among PATIENTS with gram-negative bacteremia. C. Area under 
receiver operating characteristics curves for the nSOFA to predict mortality in infants with gram-positive bacteremia at T0, 
T6, and T12 time points (all p<0.001). D. Area under receiver operating characteristics curves for the nSOFA to predict 
mortality in infants with gram-negative bacteremia at T0, T6, and T12 time points (all p<0.001). E. Comparison of nSOFA 
scores among survivors with gram-positive or gram-negative bacteremia. F. Comparison of nSOFA scores among non-
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eFigure 12. nSOFA scores among patients with surgical peritonitis and negative blood 
cultures. A. Violin plots represent group medians at each time point. Error bars represent interquartile ranges (IQR). B. 
Area under receiver operating characteristics curve (AUROC) for death shown for T0 (squares), T6 (triangles), and T12 
(circles) time points. All AUROCs with p<0.001. Comparisons by Mann-Whitney. * designates p-value <0.001. ** 
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eAppendix. Neonatal Sequential Organ Failure Assessment (nSOFA)  
nSOFA Background 
One of the primary charges of the group that developed The Third International Consensus Definitions for Sepsis and Septic 
Shock (Sepsis-3) was to differentiate sepsis from uncomplicated infection.1 As the authors of the Sepsis-3 guidelines stated:  
1. “Sepsis involves organ dysfunction, indicating a pathobiology more complex than infection plus an accompanying 
inflammatory response alone”.  
2. “For clinical operationalization, organ dysfunction can be represented by an increase in the Sequential [Sepsis-related] 
Organ Failure Assessment (SOFA) score of 2 points or more, which is associated with an in-hospital mortality greater 
than 10%”.  
3. “The SOFA score is not intended to be used as a tool for patient management but as a means to clinically characterize a 
septic patient.” 
Thus, the SOFA score, and the nSOFA score are not used to determine initiation, continuation, or discontinuation of antibiotics, but 
rather to differentiate infection from sepsis by measuring the risk of death. In adults, the prerequisite to a diagnosis of sepsis supported 
by the SOFA score is “suspected infection”; evidenced by the clinical decision to send blood/body fluids for culture and start 
antibiotics.1 For the retrospective, multi-center arm of this study to determine generalizability of the nSOFA to predict mortality with 
late-onset infection, the nSOFA was studied in patients with definitive infection (bacteremia or surgical peritonitis). 
nSOFA components 
The present study aimed to determine the generalizability of the nSOFA score. The nSOFA components and scoring paradigms were 
modeled after the adult SOFA and the pediatric SOFA.1-3 As with the SOFA and pSOFA, nSOFA components and cutoffs aim to 
identify and quantify the severity the organ dysfunction that is associated with infection-related mortality. The derivation and single-
center validation of the score has been previously described.2, 4 The nSOFA utilizes only objective and clinical standard-of-care data to 
provide a serial measure of organ dysfunction that predicts mortality risk among preterm infants with late-onset infection. Importantly, 
the scoring designations within each system are not arranged as a reflection of the timing, sequence, or appropriateness of the 
interventions. In the studies that informed the development of the nSOFA4, patients that died with late-onset bacteremia showed nearly 
universal receipt of intubation and mechanical ventilation as well as a doubling in oxygen requirement. The high prevalence of 
respiratory dysfunction associated with death compared to the prevalence of other organ dysfunctions justifies a greater weight in the 
score. The use of inotropic and vasoactive medications is associated with a high risk of mortality during infection.5 However, we 
found nearly 60% of those that died with late-onset bacteremia never received inotropic or vasoactive medications.4 To ensure 
generalizability, the nSOFA score uses the most recent platelet count available to the clinician. Multiple measurements of platelets 
would be considered outside clinical practice and thus the results obtained using that approach would not be generalizable. As a result, 
a single platelet measurement, sent at the discretion of the clinician, may be used in the calculation of more than one nSOFA score. 
There were no instances for any patient in this study where a platelet measure was unavailable.  
Systems not included in nSOFA 
The adult SOFA and pSOFA include component scores from six systems: respiration, coagulation, cardiovascular, liver, renal, and 
central nervous system. The nSOFA includes assessments of respiratory, cardiovascular, and hematologic dysfunction, but does not 
include assessments of renal, hepatic, or central nervous system dysfunction. We argue these exclusions are justified concurrently by 
the following rationale: 
1) Total bilirubin is the component used to measure liver dysfunction in the SOFA. Bilirubin measures, while potentially 
informative in critically-ill children and adults, are complicated by protracted physiologic jaundice in preterm neonates.  
2) In contrast to adults and children, where continuous renal replacement therapy (CRRT) is used to mitigate renal failure, the 
use of CRRT in neonates is extremely rare in the absence of severe congenital kidney disease. Furthermore, the current 
definition of acute kidney injury in neonates is an increase in serum creatinine of >0.3 mg/dL or >50% from the previous 
lowest value, or a urinary output of less than 1 mL/kg per hour on post-natal days 2-7.6 Outside of the post-natal age 
restrictions that would decrease generalizability past the first week of life, both creatinine and urine output have multiple co-
covariates including post-natal age, fluid intake, presence of hypotension, concurrent use of diuretics, systemic 
glucocorticoids, antidiuretic hormone concentrations that may occur with central nervous system injury, gestational age, and 
maternal creatinine.   
3) Objective central nervous system functional assessments applicable to preterm infants are not well-established and thus not 
commonly used in the NICU population. Descriptive characteristics commonly used such as “lethargy” are highly-
subjective. Other assessments including tone and responsiveness to touch or pain are affected by gestational age and the 
presence of sedation.  
Based on these many limitations, central nervous system, renal, and hepatic system assessments were not included in the present 
iteration of the nSOFA. Additionally, neither the total white blood cell count nor the absolute neutrophil count are included in the 
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